Verition Fund Management LLC

Position in NVS — Novartis AG

CIK 1454027 GREENWICH, CT

Back to NVS Full portfolio

Position in NVS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,567,200

+$1,130,335 QoQ

Shares Held

10,000

+249.7% QoQ

Ownership

0.001%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#492

of 1,603 holders

Holding Since

Jun 2020

6 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVS Over Time

Shares Held

Position Value (USD)

Derivatives in NVS

reported options exposure · as of Jun 30, 2026

CallValue

$1,567,200

CallShares

10,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

Verition Fund Management LLC holds $84,469,411 across 15 Drug Manufacturers - General names. NVS ranks #11 (1.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	JNJ	Johnson & Johnson	159,049	$40,393,674
2	MRK	Merck & Co., Inc.	53,638	$6,892,483
3	OGN	Organon & Co.	497,996	$6,742,865
4	BIIB	Biogen Inc.	30,914	$6,679,278
5	LLY	ELI LILLY & Co	3,365	$4,036,082
6	GRFS	Grifols SA	550,746	$3,899,281
7	ABBV	AbbVie Inc.	14,719	$3,703,889
8	SNY	Sanofi	65,000	$2,772,900

All Filings in NVS

Export CSV

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,567,200	10,000	+249.7%	Shares	Sole	2026-08-14
2026-06-30	$1,567,200	10,000	+112.8%	Call	Sole	2026-08-14
2026-03-31	$436,865	2,860	-61.9%	Shares	Sole	2026-05-15
2025-12-31	$1,034,852	7,506	+116.7%	Shares	Sole	2026-02-13
2024-12-31	$337,081	3,464	+29.4%	Shares	Sole	2025-02-14
2022-03-31	$412,425	4,700	—	Call	Sole	2022-06-02
2022-03-31	$280,800	3,200	—	Put	Sole	2022-06-02
2020-06-30	$233,721	2,676	—	Shares	Sole	2020-08-14
No filing history on record for this holder in this stock.